NeuroOne stock rallies after FDA clears its OneRF system, a minimally invasive solution targeting severe facial pain, scheduled to launch in late 2025.

NeuroOne has obtained 510(k) clearance from the FDA for its OneRF trigeminal nerve ablation system to treat facial pain.

Neuroone Medical Technologies Corp. expanded into treatment of chronic pain with a new U.S. FDA clearance for use of its Onerf system to treat trigeminal nerve pain. The system uses radiofrequency ...

Trigeminal nerve ablation, a minimally invasive procedure, uses RF energy to destroy abnormal tissue and relieve severe, ...

NeuroOne Medical Technologies ( ($NMTC) ) has provided an announcement. On August 18, 2025, NeuroOne Medical Technologies Corporation announced it ...

FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments EDEN PRAIRIE, Minn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical ...

Technologies has received U.S. Food and Drug Administration, FDA, clearance to market its OneRF Trigeminal Nerve Ablation ...

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Q3 2025 Earnings Call Transcript August 14, 2025 NeuroOne Medical Technologies Corporation beats earnings expectations. Reported EPS is $-0.03, ...

NeuroOne Medical Technologies(NASDAQ:NMTC) reported fiscal third quarter 2025 earnings on August 14, 2025, with product revenue up 105% year-over-year to $1.7 million and product gross margins rising ...

Ronald W. McClurg, CFO, said, "product revenue increased 105% to $1.7 million" and cited "sizable improvements year-over-year ...

Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 ...

Key Points Earnings per share (GAAP) improved to $(0.03) in Q3 FY2025, beating the analyst estimate of $(0.05). Revenue (GAAP) climbed 105% year over year to $1.7 million in Q3 FY2025, missing analyst ...